• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

21.01 -0.96 (-4.37%)
Streaming Delayed Price Updated: 2:37 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,639,575
Open 21.44
Bid (Size) 20.99 (4)
Ask (Size) 21.01 (1)
Prev. Close 21.97
Today's Range 20.17 - 22.34
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
An Overview of Summit Therapeutics's Earnings
Today 10:01 EDT
 
Via Benzinga
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
Today 7:00 EDT
From Summit Therapeutics
Via Business Wire

Performance

YTD
+14.5%
+14.5%
1 Month
+15.9%
+15.9%
3 Month
-24.0%
-24.0%
6 Month
-14.6%
-14.6%
1 Year
-10.4%
-10.4%

More News

Read More
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
October 15, 2025
From Summit Therapeutics
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
October 08, 2025
Via Benzinga
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
September 16, 2025
Via Stocktwits
1 Monster Stock in the Making to Buy and Hold
October 05, 2025
Via The Motley Fool
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence
October 01, 2025
Via Benzinga
Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio?
September 28, 2025
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 24, 2025
From Pomerantz LLP
Via GlobeNewswire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2025
From Summit Therapeutics
Via Business Wire
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
September 24, 2025
From Summit Therapeutics
Via Business Wire
Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends
September 23, 2025
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
September 17, 2025
Via Benzinga
Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock
September 15, 2025
Via Benzinga
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
September 14, 2025
Via Benzinga
Topics Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 14, 2025
From Pomerantz LLP
Via GlobeNewswire
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
September 10, 2025
Via Investor's Business Daily
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 10, 2025
From Pomerantz LLP
Via GlobeNewswire
Top 3 Health Care Stocks You'll Regret Missing In Q3
September 09, 2025
Via Benzinga
Is Summit Therapeutics a Buy, Sell, or Hold Now?
September 09, 2025
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
September 08, 2025
Via Benzinga
Gold Moves Higher; Robinhood Shares Jump
September 08, 2025
Via Benzinga
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
September 08, 2025
Via Investor's Business Daily
Top movers in Monday's pre-market session
September 08, 2025
Via Chartmill
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
September 08, 2025
Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 21.01
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 10/17/25 02:37 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 2.05B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap